Genmab, Seattle Genetics to Present at ESMO 2018

• Data presented from updated analysis of full innovaTV 201 expansion cohort in recurrent or metastatic cervical cancer

Genmab A/S (Nasdaq Copenhagen: GEN) and Seattle Genetics, Inc. (Nasdaq: SGEN) announced today that updated clinical data from the innovaTV 201 Phase II study evaluating tisotumab vedotin in patients with recurrent and/or metastatic cervical cancer will be presented as a poster at the European Society for Medical Oncology (ESMO) 2018 Congress taking place in Munich, Germany from October 19 to 23, 2018. Tisotumab vedotin is an investigational antibody-drug conjugate (ADC) designed to target the Tissue Factor antigen, which is expressed on a broad range of solid tumors.

https://www.marketscreener.com/SEATTLE-GENETICS-INC-10808/news/Seattle-Genetics-Genmab-and-Seattle-Genetics-Announce-Tisotumab-Vedotin-Data-to-Be-Presented-at-ES-27388241/